Analysts Set Vor Biopharma Inc. (NYSE:VOR) Target Price at $11.36

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) has been given an average recommendation of "Buy" by the seven research firms that are currently covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $11.36.

A number of brokerages have commented on VOR. HC Wainwright restated a "buy" rating and issued a $17.50 price target on shares of Vor Biopharma in a research report on Tuesday, December 10th. Robert W. Baird reduced their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an "outperform" rating on the stock in a research report on Friday, November 8th. Wedbush reissued an "outperform" rating and set a $11.00 price target on shares of Vor Biopharma in a research note on Monday, December 9th. Finally, JMP Securities restated a "market outperform" rating and issued a $12.00 target price on shares of Vor Biopharma in a report on Tuesday, December 10th.

Vor Biopharma Trading Down 4.6 %

NYSE VOR traded down $0.08 during trading hours on Friday, hitting $1.56. 589,791 shares of the company's stock traded hands, compared to its average volume of 1,499,345. Vor Biopharma has a 52 week low of $0.63 and a 52 week high of $3.14. The firm has a market capitalization of $106.79 million, a P/E ratio of -0.94 and a beta of -0.51. The business's fifty day moving average price is $0.99 and its two-hundred day moving average price is $0.91.

Vor Biopharma (NYSE:VOR - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). On average, sell-side analysts expect that Vor Biopharma will post -1.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC boosted its position in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company's stock valued at $79,000 after acquiring an additional 27,597 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company's stock worth $495,000 after purchasing an additional 160,642 shares during the last quarter. Hsbc Holdings PLC boosted its position in Vor Biopharma by 177.0% during the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company's stock valued at $51,000 after purchasing an additional 31,333 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Vor Biopharma in the second quarter valued at about $53,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Vor Biopharma in the second quarter worth about $63,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.